Laura M Bogart1, Matt G Mutchler2,3, Bryce McDavitt3,4, David J Klein5, William E Cunningham6, Kathy J Goggin7,8, Bonnie Ghosh-Dastidar5, Nikki Rachal3, Kelsey A Nogg3, Glenn J Wagner5. 1. RAND Corporation, 1776 Main Street, P.O. Box 2138, Santa Monica, CA, 90407-2138, USA. lbogart@rand.org. 2. California State University, Dominguez Hills, CA, USA. 3. AIDS Project Los Angeles, Los Angeles, CA, USA. 4. University of Southern California, Los Angeles, CA, USA. 5. RAND Corporation, 1776 Main Street, P.O. Box 2138, Santa Monica, CA, 90407-2138, USA. 6. University of California, Los Angeles, Los Angeles, CA, USA. 7. Children's Mercy Kansas City, Kansas City, MO, USA. 8. University of Missouri - Kansas City Schools of Medicine and Pharmacy, Kansas City, MO, USA.
Abstract
BACKGROUND: Evidence-based HIV treatment adherence interventions have typically shown medium-sized effects on adherence. Prior evidence-based HIV treatment adherence interventions have not been culturally adapted specifically for Black/African Americans, the population most affected by HIV disparities in the USA, who exhibit lower adherence than do members of other racial/ethnic groups. PURPOSE: We conducted a randomized controlled trial of Rise, a 6-month culturally congruent adherence counseling intervention for HIV-positive Black men and women. METHODS: Rise was delivered by a trained peer counselor who used a problem-solving approach to address culturally congruent adherence barriers (e.g., medical mistrust, HIV stigma) and assisted with linkage to supportive services. A total of 215 participants were randomized to the intervention group (n = 107) or a wait-list control group (n = 108). Adherence was assessed daily via electronic monitoring. RESULTS: In a repeated measures multivariate logistic regression model of dichotomous adherence (using a clinically significant cutoff of 85% of doses taken), adjusted for sociodemographic and medical covariates, adherence in the intervention group improved over time relative to the control group, (OR = 1.30 per month (95% CI = 1.12-1.51), p < 0.001), representing a large cumulative effect after 6 months (OR = 4.76, Cohen's d = 0.86). CONCLUSIONS: Rise showed a larger effect on adherence than prior HIV adherence intervention studies. For greater effectiveness, interventions to improve adherence among Black people living with HIV may need to be customized to address culturally relevant barriers to adherence. ( ClinicalTrials.gov #NCT01350544).
RCT Entities:
BACKGROUND: Evidence-based HIV treatment adherence interventions have typically shown medium-sized effects on adherence. Prior evidence-based HIV treatment adherence interventions have not been culturally adapted specifically for Black/African Americans, the population most affected by HIV disparities in the USA, who exhibit lower adherence than do members of other racial/ethnic groups. PURPOSE: We conducted a randomized controlled trial of Rise, a 6-month culturally congruent adherence counseling intervention for HIV-positive Black men and women. METHODS: Rise was delivered by a trained peer counselor who used a problem-solving approach to address culturally congruent adherence barriers (e.g., medical mistrust, HIV stigma) and assisted with linkage to supportive services. A total of 215 participants were randomized to the intervention group (n = 107) or a wait-list control group (n = 108). Adherence was assessed daily via electronic monitoring. RESULTS: In a repeated measures multivariate logistic regression model of dichotomous adherence (using a clinically significant cutoff of 85% of doses taken), adjusted for sociodemographic and medical covariates, adherence in the intervention group improved over time relative to the control group, (OR = 1.30 per month (95% CI = 1.12-1.51), p < 0.001), representing a large cumulative effect after 6 months (OR = 4.76, Cohen's d = 0.86). CONCLUSIONS: Rise showed a larger effect on adherence than prior HIV adherence intervention studies. For greater effectiveness, interventions to improve adherence among Black people living with HIV may need to be customized to address culturally relevant barriers to adherence. ( ClinicalTrials.gov #NCT01350544).
Authors: Jonathan Shuter; Julie A Sarlo; Tina J Kanmaz; Richard A Rode; Barry S Zingman Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Laura M Bogart; Glenn J Wagner; Matt G Mutchler; Brian Risley; Bryce W McDavitt; Tara McKay; David J Klein Journal: AIDS Educ Prev Date: 2012-02
Authors: Maureen H Rumptz; Carol Tobias; Serena Rajabiun; Judith Bradford; Howard Cabral; Robin Young; William E Cunningham Journal: AIDS Patient Care STDS Date: 2007 Impact factor: 5.078
Authors: Laura M Bogart; Glenn J Wagner; Harold D Green; Matt G Mutchler; David J Klein; Bryce McDavitt; Sean J Lawrence; Charles L Hilliard Journal: Soc Sci Med Date: 2016-03-19 Impact factor: 4.634
Authors: J Berkley-Patton; C Bowe Thompson; K Goggin; D Catley; M Berman; A Bradley-Ewing; K P Derose; K Resnicow; J Allsworth; S Simon Journal: Contemp Clin Trials Date: 2019-09-16 Impact factor: 2.226
Authors: Erik D Storholm; Laura M Bogart; Matt G Mutchler; David J Klein; Bonnie Ghosh-Dastidar; Bryce McDavitt; Glenn J Wagner Journal: AIDS Behav Date: 2019-08
Authors: Laura M Bogart; Joanna L Barreras; Ana Gonzalez; David J Klein; Terry Marsh; Denis Agniel; David W Pantalone Journal: AIDS Behav Date: 2020-11-24
Authors: Maulika Kohli; Elizabeth C Pasipanodya; Jessica L Montoya; Maria Marquine; Martin Hoenigl; Vanessa Serrano; Clint Cushman; Rogelio Garcia; John Kua; Verna Gant; Sarah Rojas; David J Moore Journal: JMIR Res Protoc Date: 2020-12-10
Authors: Catherine Orrell; Kathy Goggin; Ingrid T Katz; Laura M Bogart; Garrett M Fitzmaurice; Vincent S Staggs; Marya V Gwadz; Ingrid V Bassett; Anna Cross; Ingrid Courtney; Lungiswa Tsolekile; Regina Panda; Sonja Steck; David R Bangsberg Journal: AIDS Behav Date: 2020-10-30